MED28: A Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: MED28

NCBI ID: G80306

MED28

MED28: A Drug Target and Biomarker for Neurodegenerative Diseases

MED28 (Magicin) is a drug target (also known as a potential drug target or biomarker) that is being studied for its potential therapeutic effects in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

MED28 is a protein that is expressed in various tissues and cells throughout the body, including the brain, nervous system, and endothelial cells. It is a key regulator of the blood-brain barrier, which is a barrier that separates the brain from the surrounding blood vessels and lymphatic system. This barrier is essential for the safe delivery of drugs and other therapeutic agents to the brain, as well as for the prevention of harmful substances from entering the brain.

MED28 has been shown to be involved in various physiological processes in the brain, including the regulation of neurotransmitter signaling, the formation of blood-brain barrier, and the regulation of inflammation. It is also known to play a role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

One of the main reasons for studying MED28 is its potential as a drug target. By blocking the activity of MED28, researchers can prevent the formation of blood-brain barrier and increase the delivery of therapeutic agents to the brain. This could lead to more effective treatments for neurodegenerative diseases and other conditions that affect the brain.

In addition to its potential therapeutic uses, MED28 is also being studied as a biomarker. By measuring the level of MED28 in brain tissue or blood samples, researchers can monitor the effectiveness of different treatments and determine the potential for new treatments. This can be an important tool for identifying potential drug targets and evaluating the effectiveness of new treatments.

Overall, MED28 is a promising drug target and biomarker that is being studied for its potential therapeutic and diagnostic uses. Further research is needed to fully understand its role in various diseases and to develop effective treatments based on its properties.

Protein Name: Mediator Complex Subunit 28

Functions: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. May be part of a complex containing NF2/merlin that participates in cellular signaling to the actin cytoskeleton downstream of tyrosine kinase signaling pathways

The "MED28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MED28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets